nodes	percent_of_prediction	percent_of_DWPC	metapath
Phylloquinone—Scleroderma—Medroxyprogesterone Acetate—uterine cancer	0.0899	0.186	CcSEcCtD
Phylloquinone—GGCX—myometrium—uterine cancer	0.0429	0.116	CbGeAlD
Phylloquinone—GGCX—uterine cervix—uterine cancer	0.0334	0.0904	CbGeAlD
Phylloquinone—BGLAP—renal system—uterine cancer	0.032	0.0867	CbGeAlD
Phylloquinone—GGCX—decidua—uterine cancer	0.0318	0.0862	CbGeAlD
Phylloquinone—GGCX—renal system—uterine cancer	0.0312	0.0846	CbGeAlD
Phylloquinone—GGCX—endometrium—uterine cancer	0.0302	0.0818	CbGeAlD
Phylloquinone—GGCX—mammalian vulva—uterine cancer	0.0292	0.0791	CbGeAlD
Phylloquinone—GGCX—uterus—uterine cancer	0.0278	0.0754	CbGeAlD
Phylloquinone—BGLAP—female reproductive system—uterine cancer	0.0256	0.0694	CbGeAlD
Phylloquinone—GGCX—female reproductive system—uterine cancer	0.025	0.0678	CbGeAlD
Phylloquinone—GGCX—female gonad—uterine cancer	0.0228	0.0617	CbGeAlD
Phylloquinone—GGCX—vagina—uterine cancer	0.0226	0.0613	CbGeAlD
Phylloquinone—Phlebitis—Carboplatin—uterine cancer	0.0215	0.0445	CcSEcCtD
Phylloquinone—BGLAP—Validated transcriptional targets of AP1 family members Fra1 and Fra2—DCN—uterine cancer	0.018	0.122	CbGpPWpGaD
Phylloquinone—Necrosis—Medroxyprogesterone Acetate—uterine cancer	0.0155	0.0321	CcSEcCtD
Phylloquinone—Injection site pain—Medroxyprogesterone Acetate—uterine cancer	0.0149	0.0308	CcSEcCtD
Phylloquinone—GGCX—lymph node—uterine cancer	0.0146	0.0396	CbGeAlD
Phylloquinone—Injection site reaction—Medroxyprogesterone Acetate—uterine cancer	0.0121	0.025	CcSEcCtD
Phylloquinone—Necrosis—Dactinomycin—uterine cancer	0.0121	0.025	CcSEcCtD
Phylloquinone—Swelling—Progesterone—uterine cancer	0.0111	0.0229	CcSEcCtD
Phylloquinone—BGLAP—Interleukin-11 Signaling Pathway—SOCS3—uterine cancer	0.0102	0.0691	CbGpPWpGaD
Phylloquinone—Anaphylactoid reaction—Progesterone—uterine cancer	0.0101	0.0208	CcSEcCtD
Phylloquinone—Swelling—Medroxyprogesterone Acetate—uterine cancer	0.01	0.0207	CcSEcCtD
Phylloquinone—Cyanosis—Etoposide—uterine cancer	0.00971	0.0201	CcSEcCtD
Phylloquinone—Anaphylactoid reaction—Medroxyprogesterone Acetate—uterine cancer	0.00913	0.0189	CcSEcCtD
Phylloquinone—Necrosis—Etoposide—uterine cancer	0.00875	0.0181	CcSEcCtD
Phylloquinone—BGLAP—Glucocorticoid receptor regulatory network—IRF1—uterine cancer	0.00844	0.0573	CbGpPWpGaD
Phylloquinone—BGLAP—Interleukin-11 Signaling Pathway—BIRC5—uterine cancer	0.00842	0.0571	CbGpPWpGaD
Phylloquinone—Sweating increased—Progesterone—uterine cancer	0.00821	0.017	CcSEcCtD
Phylloquinone—Phlebitis—Dactinomycin—uterine cancer	0.008	0.0165	CcSEcCtD
Phylloquinone—Pain—Carboplatin—uterine cancer	0.0078	0.0161	CcSEcCtD
Phylloquinone—Sweating increased—Medroxyprogesterone Acetate—uterine cancer	0.00744	0.0154	CcSEcCtD
Phylloquinone—BGLAP—Validated transcriptional targets of AP1 family members Fra1 and Fra2—CCL2—uterine cancer	0.00735	0.0499	CbGpPWpGaD
Phylloquinone—BGLAP—FGF signaling pathway—FGFR2—uterine cancer	0.00721	0.0489	CbGpPWpGaD
Phylloquinone—Inflammation—Etoposide—uterine cancer	0.00708	0.0146	CcSEcCtD
Phylloquinone—Sweating—Medroxyprogesterone Acetate—uterine cancer	0.00653	0.0135	CcSEcCtD
Phylloquinone—BGLAP—Validated transcriptional targets of AP1 family members Fra1 and Fra2—CDKN2A—uterine cancer	0.00641	0.0435	CbGpPWpGaD
Phylloquinone—BGLAP—FGF signaling pathway—MET—uterine cancer	0.00619	0.042	CbGpPWpGaD
Phylloquinone—Immune system disorder—Progesterone—uterine cancer	0.00609	0.0126	CcSEcCtD
Phylloquinone—Erythema—Progesterone—uterine cancer	0.00587	0.0121	CcSEcCtD
Phylloquinone—BGLAP—Validated transcriptional targets of AP1 family members Fra1 and Fra2—CXCL8—uterine cancer	0.00581	0.0394	CbGpPWpGaD
Phylloquinone—Phlebitis—Etoposide—uterine cancer	0.00579	0.012	CcSEcCtD
Phylloquinone—GGCX—Metabolism of proteins—TSPYL2—uterine cancer	0.00575	0.039	CbGpPWpGaD
Phylloquinone—Swelling—Etoposide—uterine cancer	0.00565	0.0117	CcSEcCtD
Phylloquinone—Immune system disorder—Medroxyprogesterone Acetate—uterine cancer	0.00552	0.0114	CcSEcCtD
Phylloquinone—BGLAP—FGF signaling pathway—CDH1—uterine cancer	0.00537	0.0364	CbGpPWpGaD
Phylloquinone—Erythema—Medroxyprogesterone Acetate—uterine cancer	0.00532	0.011	CcSEcCtD
Phylloquinone—BGLAP—Regulation of retinoblastoma protein—MET—uterine cancer	0.00528	0.0358	CbGpPWpGaD
Phylloquinone—Anaphylactoid reaction—Etoposide—uterine cancer	0.00515	0.0107	CcSEcCtD
Phylloquinone—BGLAP—Validated transcriptional targets of AP1 family members Fra1 and Fra2—EP300—uterine cancer	0.00498	0.0338	CbGpPWpGaD
Phylloquinone—Necrosis—Epirubicin—uterine cancer	0.00491	0.0101	CcSEcCtD
Phylloquinone—Anaphylactic shock—Progesterone—uterine cancer	0.00479	0.00991	CcSEcCtD
Phylloquinone—Injection site pain—Epirubicin—uterine cancer	0.00472	0.00975	CcSEcCtD
Phylloquinone—BGLAP—Notch-mediated HES/HEY network—CDKN1B—uterine cancer	0.00469	0.0318	CbGpPWpGaD
Phylloquinone—Hyperhidrosis—Progesterone—uterine cancer	0.00463	0.00958	CcSEcCtD
Phylloquinone—Necrosis—Doxorubicin—uterine cancer	0.00454	0.00939	CcSEcCtD
Phylloquinone—Hypotension—Progesterone—uterine cancer	0.00448	0.00926	CcSEcCtD
Phylloquinone—Flushing—Dactinomycin—uterine cancer	0.00442	0.00915	CcSEcCtD
Phylloquinone—Injection site pain—Doxorubicin—uterine cancer	0.00436	0.00903	CcSEcCtD
Phylloquinone—Anaphylactic shock—Medroxyprogesterone Acetate—uterine cancer	0.00434	0.00898	CcSEcCtD
Phylloquinone—Dyspnoea—Progesterone—uterine cancer	0.00427	0.00883	CcSEcCtD
Phylloquinone—Hyperbilirubinaemia—Epirubicin—uterine cancer	0.00424	0.00876	CcSEcCtD
Phylloquinone—Sweating increased—Etoposide—uterine cancer	0.0042	0.00868	CcSEcCtD
Phylloquinone—Hyperhidrosis—Medroxyprogesterone Acetate—uterine cancer	0.0042	0.00868	CcSEcCtD
Phylloquinone—Erythema—Dactinomycin—uterine cancer	0.00415	0.00858	CcSEcCtD
Phylloquinone—BGLAP—Notch-mediated HES/HEY network—EP300—uterine cancer	0.00411	0.0279	CbGpPWpGaD
Phylloquinone—Pain—Progesterone—uterine cancer	0.0041	0.00847	CcSEcCtD
Phylloquinone—Hypotension—Medroxyprogesterone Acetate—uterine cancer	0.00406	0.00839	CcSEcCtD
Phylloquinone—BGLAP—Regulation of retinoblastoma protein—CDKN2A—uterine cancer	0.00403	0.0274	CbGpPWpGaD
Phylloquinone—Inflammation—Epirubicin—uterine cancer	0.00397	0.00821	CcSEcCtD
Phylloquinone—Hyperbilirubinaemia—Doxorubicin—uterine cancer	0.00392	0.0081	CcSEcCtD
Phylloquinone—Dyspnoea—Medroxyprogesterone Acetate—uterine cancer	0.00387	0.008	CcSEcCtD
Phylloquinone—Injection site reaction—Epirubicin—uterine cancer	0.00383	0.00792	CcSEcCtD
Phylloquinone—Inflammation—Doxorubicin—uterine cancer	0.00367	0.0076	CcSEcCtD
Phylloquinone—BGLAP—Regulation of retinoblastoma protein—CDKN1B—uterine cancer	0.00357	0.0242	CbGpPWpGaD
Phylloquinone—Injection site reaction—Doxorubicin—uterine cancer	0.00354	0.00733	CcSEcCtD
Phylloquinone—Hypersensitivity—Progesterone—uterine cancer	0.00353	0.0073	CcSEcCtD
Phylloquinone—Phlebitis—Epirubicin—uterine cancer	0.00325	0.00671	CcSEcCtD
Phylloquinone—Flushing—Etoposide—uterine cancer	0.0032	0.00662	CcSEcCtD
Phylloquinone—Hypersensitivity—Medroxyprogesterone Acetate—uterine cancer	0.0032	0.00662	CcSEcCtD
Phylloquinone—Dizziness—Progesterone—uterine cancer	0.00317	0.00655	CcSEcCtD
Phylloquinone—BGLAP—Regulation of retinoblastoma protein—EP300—uterine cancer	0.00314	0.0213	CbGpPWpGaD
Phylloquinone—Immune system disorder—Etoposide—uterine cancer	0.00312	0.00644	CcSEcCtD
Phylloquinone—BGLAP—Glucocorticoid receptor regulatory network—CXCL8—uterine cancer	0.00307	0.0209	CbGpPWpGaD
Phylloquinone—Phlebitis—Doxorubicin—uterine cancer	0.003	0.00621	CcSEcCtD
Phylloquinone—BGLAP—Interleukin-11 Signaling Pathway—HRAS—uterine cancer	0.00297	0.0201	CbGpPWpGaD
Phylloquinone—Pain—Dactinomycin—uterine cancer	0.0029	0.00599	CcSEcCtD
Phylloquinone—Anaphylactoid reaction—Epirubicin—uterine cancer	0.00289	0.00597	CcSEcCtD
Phylloquinone—Dizziness—Medroxyprogesterone Acetate—uterine cancer	0.00287	0.00594	CcSEcCtD
Phylloquinone—BGLAP—FGF signaling pathway—PIK3CA—uterine cancer	0.00272	0.0185	CbGpPWpGaD
Phylloquinone—Anaphylactoid reaction—Doxorubicin—uterine cancer	0.00267	0.00553	CcSEcCtD
Phylloquinone—BGLAP—Glucocorticoid receptor regulatory network—EP300—uterine cancer	0.00264	0.0179	CbGpPWpGaD
Phylloquinone—BGLAP—Interleukin-11 Signaling Pathway—AKT1—uterine cancer	0.00262	0.0178	CbGpPWpGaD
Phylloquinone—GGCX—Metabolism of proteins—INHBA—uterine cancer	0.00257	0.0174	CbGpPWpGaD
Phylloquinone—Hypersensitivity—Dactinomycin—uterine cancer	0.0025	0.00516	CcSEcCtD
Phylloquinone—Anaphylactic shock—Etoposide—uterine cancer	0.00245	0.00507	CcSEcCtD
Phylloquinone—GGCX—Metabolism of proteins—MME—uterine cancer	0.00242	0.0164	CbGpPWpGaD
Phylloquinone—Hyperhidrosis—Etoposide—uterine cancer	0.00237	0.0049	CcSEcCtD
Phylloquinone—Hypotension—Etoposide—uterine cancer	0.00229	0.00474	CcSEcCtD
Phylloquinone—BGLAP—FGF signaling pathway—AKT1—uterine cancer	0.00223	0.0151	CbGpPWpGaD
Phylloquinone—Dyspnoea—Etoposide—uterine cancer	0.00219	0.00452	CcSEcCtD
Phylloquinone—Pain—Etoposide—uterine cancer	0.0021	0.00433	CcSEcCtD
Phylloquinone—Sweating—Epirubicin—uterine cancer	0.00207	0.00427	CcSEcCtD
Phylloquinone—Sweating—Doxorubicin—uterine cancer	0.00191	0.00395	CcSEcCtD
Phylloquinone—BGLAP—Glucocorticoid receptor regulatory network—TP53—uterine cancer	0.00189	0.0128	CbGpPWpGaD
Phylloquinone—Hypersensitivity—Etoposide—uterine cancer	0.00181	0.00373	CcSEcCtD
Phylloquinone—Flushing—Epirubicin—uterine cancer	0.00179	0.00371	CcSEcCtD
Phylloquinone—Immune system disorder—Epirubicin—uterine cancer	0.00175	0.00361	CcSEcCtD
Phylloquinone—Erythema—Epirubicin—uterine cancer	0.00168	0.00348	CcSEcCtD
Phylloquinone—Flushing—Doxorubicin—uterine cancer	0.00166	0.00343	CcSEcCtD
Phylloquinone—Dizziness—Etoposide—uterine cancer	0.00162	0.00335	CcSEcCtD
Phylloquinone—Immune system disorder—Doxorubicin—uterine cancer	0.00162	0.00334	CcSEcCtD
Phylloquinone—BGLAP—Glucocorticoid receptor regulatory network—AKT1—uterine cancer	0.00159	0.0108	CbGpPWpGaD
Phylloquinone—GGCX—Metabolism of proteins—FBXW7—uterine cancer	0.00159	0.0108	CbGpPWpGaD
Phylloquinone—Erythema—Doxorubicin—uterine cancer	0.00156	0.00322	CcSEcCtD
Phylloquinone—Anaphylactic shock—Epirubicin—uterine cancer	0.00137	0.00284	CcSEcCtD
Phylloquinone—Hyperhidrosis—Epirubicin—uterine cancer	0.00133	0.00275	CcSEcCtD
Phylloquinone—Hypotension—Epirubicin—uterine cancer	0.00128	0.00265	CcSEcCtD
Phylloquinone—Anaphylactic shock—Doxorubicin—uterine cancer	0.00127	0.00263	CcSEcCtD
Phylloquinone—Hyperhidrosis—Doxorubicin—uterine cancer	0.00123	0.00254	CcSEcCtD
Phylloquinone—Dyspnoea—Epirubicin—uterine cancer	0.00123	0.00253	CcSEcCtD
Phylloquinone—Hypotension—Doxorubicin—uterine cancer	0.00119	0.00246	CcSEcCtD
Phylloquinone—Pain—Epirubicin—uterine cancer	0.00118	0.00243	CcSEcCtD
Phylloquinone—Dyspnoea—Doxorubicin—uterine cancer	0.00113	0.00234	CcSEcCtD
Phylloquinone—Pain—Doxorubicin—uterine cancer	0.00109	0.00225	CcSEcCtD
Phylloquinone—Hypersensitivity—Epirubicin—uterine cancer	0.00101	0.00209	CcSEcCtD
Phylloquinone—Hypersensitivity—Doxorubicin—uterine cancer	0.000937	0.00194	CcSEcCtD
Phylloquinone—Dizziness—Epirubicin—uterine cancer	0.000909	0.00188	CcSEcCtD
Phylloquinone—Dizziness—Doxorubicin—uterine cancer	0.000841	0.00174	CcSEcCtD
Phylloquinone—GGCX—Metabolism of proteins—CCL2—uterine cancer	0.000816	0.00554	CbGpPWpGaD
Phylloquinone—GGCX—Metabolism of proteins—CXCL8—uterine cancer	0.000645	0.00438	CbGpPWpGaD
Phylloquinone—GGCX—Metabolism of proteins—CTNNB1—uterine cancer	0.000595	0.00404	CbGpPWpGaD
